On Tuesday, biopharmaceutical company Candel Therapeutics, Inc. (CADL), announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to their oncology drug candidate, Can-3110.
Can-3110 is a pioneering oncology viral immunotherapy treatment designed specifically for patients with recurrent high-grade glioma, a type of brain tumor. The drug aims to improve overall survival rates for these patients.
Paul Peter Tak, President and CEO of Candel, mentioned that more information, including the effects of administering multiple injections, will be released following the conclusion of the phase 1b clinical trial in the latter half of 2024.
The company also indicated its intentions to begin the preliminary new drug process for a second product, characterized by Nestin expression.
